Login / Signup
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA.
Samuel E Gandy
David S Knopman
Mary Sano
Published in:
Molecular neurodegeneration (2021)
Keyphrases
</>
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
primary care
low dose
prognostic factors
patient reported outcomes